Aplastic Anemia - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Aplastic Anemia - Pipeline Review, H2 2018’, provides an overview of the Aplastic Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Aplastic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Aplastic Anemia

- The report reviews pipeline therapeutics for Aplastic Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Aplastic Anemia therapeutics and enlists all their major and minor projects

- The report assesses Aplastic Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Aplastic Anemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Aplastic Anemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Aplastic Anemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acceleron Pharma Inc

Amgen Inc

BioLineRx Ltd

Cell Source Inc

Cellenkos Inc

F. Hoffmann-La Roche Ltd

Gamida Cell Ltd

Jiangsu Hengrui Medicine Co Ltd

Regen ...

Acceleron Pharma Inc

Amgen Inc

BioLineRx Ltd

Cell Source Inc

Cellenkos Inc

F. Hoffmann-La Roche Ltd

Gamida Cell Ltd

Jiangsu Hengrui Medicine Co Ltd

Regen BioPharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Aplastic Anemia - Overview

Aplastic Anemia - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Aplastic Anemia - Overview

Aplastic Anemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Aplastic Anemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aplastic Anemia - Companies Involved in Therapeutics Development

Acceleron Pharma Inc

Amgen Inc

BioLineRx Ltd

Cell Source Inc

Cellenkos Inc

F. Hoffmann-La Roche Ltd

Gamida Cell Ltd

Jiangsu Hengrui Medicine Co Ltd

Regen BioPharma Inc

Aplastic Anemia - Drug Profiles

Anemir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-8040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Aplastic Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Aplastic Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Hematological Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-0801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CordIn - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXG-34217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HemaXellerate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hetrombopag Olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sotatercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aplastic Anemia - Dormant Projects

Aplastic Anemia - Discontinued Products

Aplastic Anemia - Product Development Milestones

Featured News & Press Releases

Jul 31, 2018: Kyowa Hakko Kirin submits application for additional indication for Romiplostim (Recombinant) for aplastic anemia in Japan

Oct 24, 2016: Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, for treatment of Bone Marrow Suppression Study

Sep 22, 2016: Regen BioPharma Responds to FDA Comments on Its Application for Orphan Drug Designation on its Aplastic Anemia Therapy

May 11, 2016: Regen BioPharma Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate

May 03, 2016: Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients

Jan 26, 2016: Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

Dec 15, 2015: Regen BioPharma Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate

Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions

Nov 17, 2015: Regen BioPharma Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application

Sep 25, 2015: Regen BioPharma Announces Positive Results from GLP Safety Study for HemaXellerate

Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia

Jul 21, 2015: Regen BioPharma Successfully Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study

Jul 09, 2015: Regen BioPharma Reports Successful Dosing of HemaXellerate in FDA-Requested GLP Animal Study

May 05, 2015: Regen BioPharma presents HemaXellerate at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC

Apr 22, 2015: Regen BioPharma Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Aplastic Anemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Aplastic Anemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Aplastic Anemia - Pipeline by Acceleron Pharma Inc, H2 2018

Aplastic Anemia - Pipeline by Amgen Inc, H2 2018

Aplastic Anemia - Pipeline by BioLineRx Ltd, H2 2018

Aplastic Anemia - Pipeline by Cell Source Inc, H2 2018

Aplastic Anemia - Pipeline by Cellenkos Inc, H2 2018

Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Aplastic Anemia - Pipeline by Gamida Cell Ltd, H2 2018

Aplastic Anemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Aplastic Anemia - Pipeline by Regen BioPharma Inc, H2 2018

Aplastic Anemia - Dormant Projects, H2 2018

Aplastic Anemia - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Aplastic Anemia, H2 2018 8

Number of Products under Development by Companies, H2 2018 9

Number ...

List of Figures

Number of Products under Development for Aplastic Anemia, H2 2018 8

Number of Products under Development by Companies, H2 2018 9

Number of Products by Targets, H2 2018 14

Number of Products by Stage and Targets, H2 2018 14

Number of Products by Mechanism of Actions, H2 2018 16

Number of Products by Stage and Mechanism of Actions, H2 2018 16

Number of Products by Routes of Administration, H2 2018 18

Number of Products by Stage and Routes of Administration, H2 2018 18

Number of Products by Molecule Types, H2 2018 20

Number of Products by Stage and Molecule Types, H2 2018 20

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports